Global Epilepsy Market Synopsis:

The Global “Epilepsy Market” research 2019 highlights the major details and provides in-depth analysis of the market along with the future growth, prospects and Industry demands analysis explores with the help of complete report with 50 Pages, figures, graphs and table of contents to analyze the situations of global Epilepsy Market and Assessment to 2023.

This report studies the Global Epilepsy Market over the forecast period of 2019 to 2023. The Global Epilepsy Market is expected to grow at an impressive Compound Annual Growth Rate (CAGR) from 2019 to 2023.

Get Sample Study Papers of “Global Epilepsy Market” @ https://www.businessindustryreports.com/sample-request/162955 .

Global Epilepsy Market 2019 - 2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the use of Epilepsyacross several end-user industries.

According to Market Analysis, The geriatric populace diagnosed with the same can significantly drive the Epilepsy Market growth. The spike in neurological disorders such as depression and Parkinson’s is predicted to fuel the epilepsy market growth. The influx of capital by research institutes to expedite the development of drugs for the treatment of seizures caused by epilepsy is likely to bolster the market demand.

Regionally, Americas held a Strong market share in 2018 and is projected to hold its position in the global marketplace through the forecast period. Europe, on the other hand, is an important growth pocket expected to reflect a high CAGR over the review period. The region is anticipated to witness inflow of investments in research & development which is likely to favor the growth of the market.

MajorPlayers profiled in the Epilepsy Market report incorporate: Eisai Co. Ltd, Novartis AG, Pfizer Inc, GW Pharmaceuticals PLC, Abbott Laboratories, UCB SA, LivaNova PLC, Medtronic PLC, Johnson & Johnson Services, GlaxoSmithKline PLC, and NeuroPace Inc.

Latest Industry News

1 GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX (cannabidiol) oral solution CV is now available in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018, is the first prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs.

“EPIDIOLEX is a much-needed new treatment option for patients with LGS, a rare and severe form of childhood-onset epilepsy that typically persists into adulthood,” said Christina SanInocencio, Executive Director of the Lennox-Gastaut Syndrome Foundation. “Despite the use of multiple epilepsy treatments, the majority of LGS patients continue to have life-long, debilitating seizures and our community welcomes the availability of a new, first-in-class treatment option.”

2 Novartis announced that the US Food and Drug Administration (FDA) has approved Mayzent(siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis (SPMS) with active disease, relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS). SPMS is a debilitating form of multiple sclerosis (MS) characterized by progressive and irreversible neurological disability. Mayzent is expected to be available in the US in approximately one week. Patients will not require a first dose observation (FDO, cardiac monitoring upon initiation) unless they have certain pre-existing cardiac conditions.

Request a Discount on standard prices of this premium report @ https://www.businessindustryreports.com/check-discount/162955 .

Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Epilepsy in these regions, from 2014 to 2023 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America.

Significant points in table of contents: Market Definition, Market Overview, Business Introduction, Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation (Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost Analysis, and Conclusion.

Report contents include

1 Analysis of the Epilepsy Marketincluding revenues, future growth, market outlook

2 Historical data and forecast

3 Regional analysis including growth estimates

4 Analyzes the end user markets including growth estimates.

5 Profiles on Epilepsyincluding products, sales/revenues, and market position

6 Market structure, market drivers and restraints.

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

[email protected]

+19376349940